News & Updates

The combination of bevacizumab and irinotecan (BEV+IRI) as second-line treatment of glioblastoma (GBM) results in better median progression-free (PFS) and overall survival (OS) when compared with historical controls, and its toxicity profile is comparable to published data, reports a study.

Exposure to any antibiotics appears to contribute to an increase in the risk of esophageal adenocarcinoma (EAC), with the risk rising as the cumulative days of exposure increases, according to a study.

New drug applications approved by US FDA as of 16-31 March 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with tenofovir disoproxil fumarate (TDF) yields similar rates of recurrence and overall survival as does entecavir in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), according to a study.

In Singapore, public awareness of oral cancer is limited compared with other common cancers, a survey suggests.

More than 6 cycles of extended adjuvant temozolomide (TMZ) therapy may result in better overall (OS) and progression-free survival (PFS) in patients with glioblastoma multiform, suggests a study.